BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 505 filers reported holding BIO-TECHNE CORP in Q2 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
|Broadcrest Asset Management, LLC||300,000||$24,489,000||21.05%|
|Montanaro Asset Management Ltd||388,800||$31,737,744||5.02%|
|Sandhill Capital Partners LLC||502,447||$41,014,775||3.74%|
|Brown Capital Management||3,160,892||$258,023,614||3.66%|
|DF DENT & CO INC||3,275,617||$267,388,640||3.62%|
|Ownership Capital B.V.||2,282,104||$186,288,150||3.26%|
|Jackson Square Partners, LLC||1,361,789||$111,162,836||3.24%|
|STONE RUN CAPITAL, LLC||88,135||$7,194,460||3.20%|
|Pembroke Management, LTD||339,591||$27,720,813||2.99%|
|Summit Creek Advisors LLC||283,693||$23,157,860||2.90%|